Sangamo Therapeutics (SGMO): Ready To Start Accumulating Ahead Of A Pivotal 2023
Sangamo is making progress across their pipeline programs. Read more to see why I am willing to accumulate a hefty position in SGMO stock.
Source: seekingalpha.com
Sell Targets News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Sell Targets. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Sell Targets Today - Breaking & Trending Today
Collegium Pharmaceutical Q3: Changing Strategy After Earnings Beat (NASDAQ:COLL)
Collegium's new products from the BDSI acquisition have already helped it report record revenue. Read more to see my strategy to accumulate COLL stock.
Source: seekingalpha.com
VBI Vaccines (VBIV): Recent Updates Have Fortified My Long-Term Outlook
VBI announced that Valneva will be their European partner for PreHevbrio. Read here if VBIV stock is a buy.
Source: seekingalpha.com
Pacific Biosciences: A Prime Candidate For My 'Bio Boom' Portfolio (PACB)
PacBio’s HiFi and SMRT sequencing technology continues to fuel growth. PACB believes itself to be on track to hit its full-year revenue guidance of ~$160-$170M. See why I rate PACB as a buy.
Source: seekingalpha.com